Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

Collaboration between UFS and Mayo Clinic to revolutionise cancer treatment
2014-06-27



Attending the lecture were, from the left: Dr Chantel Swart, Prof Lodewyk Kock, Prof Debabrata Mukhopadhyay, Prof James du Preez; back: Prof Pieter van Wyk.
Dr Swart, Profs Kock and Du Preez are from the Department of Microbial, Biochemical and Food Biotechnology. Prof Mukhopadhyay is from the Mayo Clinic (US) and Prof Van Wyk is from the Centre for Microscopy at the UFS.
Photo: Supplied
The UFS made a discovery that may have enormous implications for the treatment of diseases in humans.

Since the discovery, the UFS joined forces with the Mayo Clinic in Rochester, US, in the fight against cancer.

In this collective effort, UFS researchers would be able to assist the Mayo team to:
• see how treatment in cancer patients is progressing,
• target treatments more effectively,
• reduce dosages in order to make treatment gentler on the patient,
• track the effectiveness of the chemotherapy drugs used, and
• gain an accurate view of how the cancer is being eliminated.

Prof Lodewyk Kock, Outstanding Professor at the Department of Microbial, Biochemical and Food Biotechnology, and his team incidentally created a technique to use argon gas particles for the first time on biological material to slice open cells to look inside.

The team that supported Prof Kock includes Dr Chantel Swart, Khumisho Dithebe (PhD student), Prof Hendrik Swart (Department of Physics) and Prof Pieter van Wyk (Centre for Microscopy).

Prof Debabrata Mukhopadhyay from the Mayo Clinic in Rochester, US, got to hear about this breakthrough at the UFS and a collaboration between the two institutions was established.

During a visit to the Bloemfontein Campus, Prof Mukhopadhyay explained novel techniques that make use of gold nanoparticles. These particles attach to chemotherapeutic drugs to selectively target cancer cells – dramatically decreasing the side effects to normal human cells.

For these new drugs (coupled to gold nanoparticles) to be accepted into clinical practice, visual and chemical proof is needed, though. This is where the technique developed by the UFS will play a vital role.

With the technique to look inside cells, the composition, location and metabolism of these drugs can be determined. This will aid in a proof of concept for the application of the nano-drugs. Furthermore, it will enable approval for use of these drugs in clinical trials and eventually could revolutionise cancer treatment as a whole.

For video lectures on the technique used, as well as its findings, follow these links:

1. http://vimeo.com/63643628 (Comic version for school kids)

2. http://vimeo.com/61521401 (Detailed version for fellow scientists)

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept